Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients

By LabMedica International staff writers
Posted on 21 Mar 2025

Acute kidney injury (AKI) is a common complication in COVID-19 patients, contributing to a higher risk of mortality. More...

Early detection of kidney-related issues in COVID-19 cases is crucial for improving patient outcomes. Traditional markers of kidney function, such as creatinine and cystatin C, often lack the specificity and sensitivity needed for accurate diagnosis. These markers can be influenced by factors like muscle mass, sex, nutrition, and other variables, while the estimated glomerular filtration rate (eGFR) can vary based on the method used. Now, a new study suggests that serum uromodulin (sUmod) could serve as a promising biomarker for diagnosing AKI in COVID-19 patients.

The study conducted by EUROIMMUN (Lübeck, Germany), St George Hospital (Leipzig, Germany), and various other research institutes, has found that sUmod may overcome the limitations of traditional kidney function markers. Uromodulin, a glycoprotein produced exclusively in the kidneys, is directly linked to kidney function. Compared to creatinine and cystatin C, sUmod offers greater sensitivity, allowing for earlier detection of kidney injury. The study analyzed the relationship between sUmod levels and AKI, as well as in-hospital mortality, in a cohort of 378 COVID-19 patients, including subsets with various comorbidities. AKI was diagnosed using standard laboratory parameters and sUmod, with serum uromodulin levels measured through a sensitive ELISA technique based on monoclonal antibodies, which is CE-marked for serum analysis (EUROIMMUN). Out of the 378 patients, 151 (40%) developed AKI, with 116 of these patients showing AKI at hospital admission, and 35 developing it during their stay.

The study revealed that patients with AKI had significantly lower mean sUmod levels (125 ng/ml) compared to those without AKI (215 ng/ml). Additionally, there was a strong correlation between sUmod and other AKI markers, such as serum creatinine and cystatin C. AKI patients had a higher probability of in-hospital death, with a mortality rate of 15%. Among those who died, the mean sUmod levels were significantly lower (129 ng/ml) compared to survivors (188 ng/ml). This study, published in Scientific Reports, further emphasizes the association between AKI and in-hospital death in COVID-19 patients and underscores the importance of early detection and management of AKI. The stable nature of sUmod and its analytical advantages over traditional kidney markers make it a promising candidate for clinical use. Further research is needed to explore its full clinical potential and improve risk stratification in this patient group.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.